@article{c6db10533e3648fb98882148076b54e9,
title = "Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs",
abstract = "Background and rationale for guideline development: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly affects the spine and sacroiliac joints [1]. It can also involve peripheral joints and entheses, and extra-musculoskeletal manifestations (EMMs) such as acute anterior uveitis, psoriasis and IBD. Since the previous version of the British Society for Rheumatology (BSR) axSpA guideline [2], which only included TNF inhibitors, pharmacological treatment options and strategies for axSpA have expanded, alongside rapid advancements in the treatment of EMMs as index conditions. In this increasingly complex and evolving therapeutic landscape, we aimed to update the guideline for health professionals in the UK who care for adults with axSpA.",
keywords = "axSpA, ankylosing spondylitis, biologics, extra-musculoskeletal manifestations, guideline, inflammatory bowel disease, management, psoriasis, recommendations, targeted synthetic DMARDs, treatment, uveitis",
author = "Zhao, {Sizheng Steven} and Harrison, {Stephanie R.} and Ben Thompson and Max Yates and Joe Eddison and Antoni Chan and Nick Clarke and Nadia Corp and Charlotte Davis and Lambert Felix and Kalveer Flora and Gregory, {William J.} and Jones, {Gareth T.} and Lamb, {Christopher A.} and Helena Marzo-Ortega and Murphy, {Daniel J.} and Harry Petrushkin and Virinderjit Sandhu and Raj Sengupta and Stefan Siebert and {Van Der Windt}, {Danielle A.} and Dale Webb and Yiu, {Zenas Z. N.} and Karl Gaffney",
note = "Data availability: All data are provided in online Supplementary Materials, available at Rheumatology online. Funding: S.S.Z. was supported by a National Institute for Health and Care Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant nos. 21173, 21754 and 21755) and the NIHR Manchester Biomedical Research Centre (NIHR203308). C.A.L. was supported by the NIHR Newcastle Biomedical Research Centre. H.M.O. was supported by the NIHR Leeds Biomedical Research Centre (Leeds BRC). Z.Y. is supported by a Medical Research Council Clinician Scientist Fellowship (MR/Z504026/1). The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. L.F., N.C., D.v.d.W. were funded by BSR to perform the literature review.",
year = "2025",
month = jun,
doi = "10.1093/rheumatology/keaf090",
language = "English",
volume = "64",
pages = "3234--3241",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",
}